These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

794 related articles for article (PubMed ID: 35467477)

  • 1. Exosome-transmitted circVMP1 facilitates the progression and cisplatin resistance of non-small cell lung cancer by targeting miR-524-5p-METTL3/SOX2 axis.
    Xie H; Yao J; Wang Y; Ni B
    Drug Deliv; 2022 Dec; 29(1):1257-1271. PubMed ID: 35467477
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hsa_circ_0017639 regulates cisplatin resistance and tumor growth via acting as a miR-1296-5p molecular sponge and modulating sine oculis homeobox 1 expression in non-small cell lung cancer.
    Chang F; Li J; Sun Q; Wei S; Song Y
    Bioengineered; 2022 Apr; 13(4):8806-8822. PubMed ID: 35287543
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Circ_PIP5K1A regulates cisplatin resistance and malignant progression in non-small cell lung cancer cells and xenograft murine model via depending on miR-493-5p/ROCK1 axis.
    Feng N; Guo Z; Wu X; Tian Y; Li Y; Geng Y; Yu Y
    Respir Res; 2021 Sep; 22(1):248. PubMed ID: 34537072
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Circ_0030998 Restrains Cisplatin Resistance Through Mediating miR-1323/PDCD4 Axis in Non-small Cell Lung Cancer.
    Zhu C; Jiang X; Xiao H; Guan J
    Biochem Genet; 2022 Dec; 60(6):2434-2454. PubMed ID: 35460386
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Exosomal circ_PIP5K1A regulates the progression of non-small cell lung cancer and cisplatin sensitivity by miR-101/ABCC1 axis.
    Shao N; Song L; Sun X
    Mol Cell Biochem; 2021 Jun; 476(6):2253-2267. PubMed ID: 33570734
    [TBL] [Abstract][Full Text] [Related]  

  • 6. LncRNA SNHG1 contributes to the cisplatin resistance and progression of NSCLC via miR-330-5p/DCLK1 axis.
    Ge P; Cao L; Zheng M; Yao Y; Wang W; Chen X
    Exp Mol Pathol; 2021 Jun; 120():104633. PubMed ID: 33753110
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Exosome-delivered circRNA circSYT15 contributes to cisplatin resistance in cervical cancer cells through the miR-503-5p/RSF1 axis.
    Chen Z; Xu Z; Wang Q; Wang L; Zhang H; Wang W; Zhao H; Guo Y; Cui J
    Cell Cycle; 2023 Oct; 22(20):2211-2228. PubMed ID: 37974391
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Circular RNAcirc_0076305 Promotes Cisplatin (DDP) Resistance of Non-Small Cell Lung Cancer Cells by Regulating
    Wang X; Wang H; Jiang H; Qiao L; Guo C
    Cancer Biother Radiopharm; 2023 Jun; 38(5):293-304. PubMed ID: 34339285
    [No Abstract]   [Full Text] [Related]  

  • 9. MiR-200c-3p and miR-485-5p overexpression elevates cisplatin sensitivity and suppresses the malignant phenotypes of non-small cell lung cancer cells through targeting RRM2.
    Liu Y; Zhang Y; Li Q; Xu R; Huang N
    Thorac Cancer; 2022 Jul; 13(13):1974-1985. PubMed ID: 35599447
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Circ-CUL2/microRNA-888-5p/RB1CC1 axis participates in cisplatin resistance in NSCLC via repressing cell advancement.
    Chen H; Li F; Xue Q
    Bioengineered; 2022 Feb; 13(2):2828-2840. PubMed ID: 35068326
    [TBL] [Abstract][Full Text] [Related]  

  • 11. circ_0007385 served as competing endogenous RNA for miR-519d-3p to suppress malignant behaviors and cisplatin resistance of non-small cell lung cancer cells.
    Ye Y; Zhao L; Li Q; Xi C; Li Y; Li Z
    Thorac Cancer; 2020 Aug; 11(8):2196-2208. PubMed ID: 32602212
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mechanism of METTL14-mediated m
    Gong S; Wang S; Shao M
    J Mol Med (Berl); 2022 Dec; 100(12):1771-1785. PubMed ID: 36352154
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Circ_0110498 facilitates the cisplatin resistance of non-small cell lung cancer by mediating the miR-1287-5p/RBBP4 axis.
    Hao D; Li Y; Shi J; Jiang J
    Thorac Cancer; 2023 Mar; 14(7):662-672. PubMed ID: 36691322
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Circ_0010235 confers cisplatin resistance in lung cancer by upregulating E2F7 through absorbing miR-379-5p.
    Wang L; Wang D; Xu Z; Qiu Y; Chen G; Tan F
    Thorac Cancer; 2023 Jul; 14(20):1946-1957. PubMed ID: 37277864
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Circ_0076305 regulates cisplatin resistance of non-small cell lung cancer via positively modulating STAT3 by sponging miR-296-5p.
    Dong Y; Xu T; Zhong S; Wang B; Zhang H; Wang X; Wang P; Li G; Yang S
    Life Sci; 2019 Dec; 239():116984. PubMed ID: 31647948
    [TBL] [Abstract][Full Text] [Related]  

  • 16. miR-186-5p targeting SIX1 inhibits cisplatin resistance in non-small-cell lung cancer cells (NSCLCs).
    Liu X; Zhou X; Chen Y; Huang Y; He J; Luo H
    Neoplasma; 2020 Jan; 67(1):147-157. PubMed ID: 31686523
    [TBL] [Abstract][Full Text] [Related]  

  • 17. LncRNA SNHG12 Decreases Non-Small Cell Lung Cancer Cell Sensitivity to Cisplatin by Repressing miR-525-5p and Promoting XIAP.
    Tan D; Wang S; Zhang P; Peng C; Wu T
    Ann Clin Lab Sci; 2023 Jan; 53(1):64-75. PubMed ID: 36889771
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Circular RNA hsa_circ_0000277 promotes tumor progression and DDP resistance in esophageal squamous cell carcinoma.
    Cheng J; Zhang R; Yan M; Li Y
    BMC Cancer; 2022 Mar; 22(1):238. PubMed ID: 35241028
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Upregulation of Long Noncoding RNA (lncRNA) X-Inactive Specific Transcript (XIST) is Associated with Cisplatin Resistance in Non-Small Cell Lung Cancer (NSCLC) by Downregulating MicroRNA-144-3p.
    Tian LJ; Wu YP; Wang D; Zhou ZH; Xue SB; Zhang DY; Wei YG; Liu W
    Med Sci Monit; 2019 Oct; 25():8095-8104. PubMed ID: 31659146
    [TBL] [Abstract][Full Text] [Related]  

  • 20. mir-126-5p Promotes Cisplatin Sensitivity of Non-Small-Cell Lung Cancer by Inhibiting ADAM9.
    Liu B; Wang R; Liu H
    Biomed Res Int; 2021; 2021():6622342. PubMed ID: 34055989
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 40.